Insight Molecular Diagnostics (IMDX) Long-Term Investments (2017 - 2021)

Insight Molecular Diagnostics (IMDX) has 5 years of Long-Term Investments data on file, last reported at $2.0 million in Q1 2021.

• Quarterly Long-Term Investments fell 80.87% year-over-year to $2.0 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $2.0 million (down 80.87% YoY) and the FY2020 annual result came in at $13.4 million, up 506.83% from the prior year.
• Long-Term Investments declined to $2.0 million in Q1 2021 per IMDX's latest filing, from $13.4 million in the prior quarter.
• The five-year high for Long-Term Investments was $13.9 million in Q3 2020, with the low at $120000.0 in Q4 2017.
• Average Long-Term Investments over 5 years is $4.7 million, with a median of $2.0 million recorded in 2020.
• Year-over-year, Long-Term Investments jumped 5271.21% in 2020 and sank 80.87% in 2021.
• Insight Molecular Diagnostics' Long-Term Investments stood at $120000.0 in 2017, then soared by 118.33% to $262000.0 in 2018, then surged by 743.89% to $2.2 million in 2019, then soared by 506.83% to $13.4 million in 2020, then plunged by 84.83% to $2.0 million in 2021.
• Business Quant data shows IMDX's Long-Term Investments at $2.0 million in Q1 2021, $13.4 million in Q4 2020, and $13.9 million in Q3 2020.